News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
-- Agreement leverages StrideBio’s novel, industry-leading, structure-driven capsid engineering platform and expands Sarepta’s early stage gene therapy pipeline – -- Sarepta granted an exclusive license to four CNS targets, on which StrideBio will lead early research and development inclusive of
View HTML
Toggle Summary Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2019. “EXONDYS 51® (eteplirsen) enjoyed another strong quarter, with third quarter
View HTML
Toggle Summary Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Credit Suisse 28 th Annual Healthcare Conference on Tuesday, Nov.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
CAMBRIDGE, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2019 financial results after the Nasdaq Global Market closes on Thursday, November 7, 2019 .
View HTML
Toggle Summary Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data presented earlier in 2019 -- CAMBRIDGE, Mass. , Oct.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were previously approved by the Compensation Committee of its Board of Directors under
View HTML
Toggle Summary Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
-- Webcast conference call to be held on Friday, Oct. 4, 2019 at 8:00 a.m. Eastern Time --   CAMBRIDGE, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct.
View HTML
Toggle Summary Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79 , The Duchenne Scholarship Program. This is the second year of the scholarship program which was
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.